中文摘要：

背景为在 orthotopic 肝移植(OLT ) 以后的肝的动脉复杂并发症的主要治疗学的治疗包括 thrombolysis，经皮的 transluminal angioplasty， stent 放置，和肝移植。在 OLT 以后的肝的动脉复杂并发症的预后与类型有关不仅，程度，并且预定而且仔细与选择联系了并且治疗学的方法预定。然而，没有关于这些复杂并发症的治疗的意见的一致。这研究的目的是在 25 个病人的临床的数据与肝的动脉血栓(帽子) 和肝的动脉狭窄诊断了的 OLT.Methods 以后为肝的动脉复杂并发症决定最佳的治疗() 在 2003 年 10 月和 2007 年 3 月之间回顾地被考察。治疗包括了包含 thrombolysis，经皮的 transluminal angioplasty 和 stent 放置的肝移植和干预。在有帽子的五个病人之中的结果， 3 与 thrombolysis 被对待。一个人恢复了，一个人在 thrombolysis 以后死了，因为周期性的帽子，另一一个在移植以后死于多器官失败。留下 2 个病人经历了成功的移植并且在那以后幸存。在介绍与的 12 个病人之中手术后地在 1 个月以内有， 2 个病人由于不可逆的肝失败和另外一个经历了移植 10 个病人与干预被对待。肝功能没能在 3 个病人改善，因为 ischemic 胆管炎，移植在 stent 放置以后在 4 个病人被执行。在经历肝移植的 6 个病人之中，二分别地死于 intracranial 出血和感染。介绍与的八个病人手术后地在 1 个月以后有， 5 个病人与 interventional 管理被对待并且在 stent 以后恢复了放置。在另外一个之中， 3 个病人介绍了与， 2 病人的肝功能是稳定的，一个病人由于 ischemic 胆汁管 lesion.Conclusions 收到了迟了的肝移植个性化的治疗学的政体应该在在 OLT 以后对待肝的动脉复杂并发症被采用根据手术后的时期，打字并且 ischemic 胆汁管损害是否存在。肝移植是为有肝的动脉血栓的病人的最好的治疗。Interventional 治疗没?

英文摘要：

Background The main therapeutic treatments for hepatic artery complications after orthotopic liver transplantation （OLT） include thrombolysis, percutaneous transluminal angioplasty, stent placement, and liver retransplantation. The prognosis of hepatic artery complications after OLT is not only related to the type, extent, and timing but also closely associated with the selection and timing of the therapeutic methods. However, there is no consensus of opinion regarding the treatment of these complications. The aim of this study was to determine optimal treatment for hepatic artery complications after OLT. Methods The clinical data of 25 patients diagnosed with hepatic artery thrombosis （HAT） and hepatic artery stenosis （HAS） between October 2003 and March 2007 were retrospectively reviewed. Treatments included liver retransplantation and interventions which contain thrombolysis, percutaneous transluminal angioplasty and stent placement. Results Among five patients with HAT, 3 were treated with thrombolysis. One recovered, one died after thrombolysis and another one died of multi-organ failure after retransplantation because of recurrent HAT. The remaining 2 patients underwent successful retransplantation and have survived after that. Among 12 patients presented with HAS within 1 month postoperatively, 2 patients underwent retransplantation due to irreversible liver failure and another 10 patients were treated with interventions. The liver function failed to improve in 3 patients and retransplantations were performed in 4 patients after stent placement because of ischemic cholangitis. Among 6 patients undergoing liver retransplantations, two died of intracranial hemorrhage and infection respectively. Eight patients presented with HAS after 1 month postoperatively, 5 patients were treated with interventional management and recovered after stent placement. Among another 3 patients presented with HAS, 2 patients’ liver function was stable and one patient received late liver retransplantation due to